Alaunos Therapeutics (NASDAQ:TCRT) Issues Quarterly Earnings Results, Beats Estimates By $1.74 EPS

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) posted its earnings results on Monday. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($2.05) by $1.74, FiscalAI reports.

Alaunos Therapeutics Stock Down 1.8%

Shares of NASDAQ TCRT traded down $0.03 during mid-day trading on Monday, reaching $1.60. 61,077 shares of the company were exchanged, compared to its average volume of 2,209,315. Alaunos Therapeutics has a 52 week low of $0.72 and a 52 week high of $4.50. The stock has a market capitalization of $5.30 million, a PE ratio of -0.84 and a beta of -1.02. The company’s 50 day moving average price is $1.64 and its 200 day moving average price is $2.28.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TCRT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Friday. TD Cowen began coverage on Alaunos Therapeutics in a report on Friday. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Read Our Latest Report on TCRT

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.

Further Reading

Earnings History for Alaunos Therapeutics (NASDAQ:TCRT)

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.